03 February – The science of targeted cancer treatments

Tuesday 03 February 2015, Birmingham

1-day course: Science of Targeted Cancer Treatments

Level: advanced (Designed for experienced research nurses and clinical trials staff with a biology background. Also suitable for medical students and junior doctors.)

Description: This course covers a wide range of licensed and experimental cancer treatments, explaining their mechanism of action at a molecular and cellular level. It also contains detailed information on mechanisms of drug resistance and discusses the future of personalised cancer medicine.

To book, contact: Selina Bell (selina.bell@nihr.ac.uk)


From benign beginnings to metastatic disease
  • Genomic instability as the underlying cause of the hallmarks of cancer cells
  • The hallmarks explained
  • The role of the tumour microenvironment, cancer stem cells and the EMT
Targets and treatments part 1
  • Cell communication as a key drug target
  • The development and manufacture of monoclonal antibodies (mAb’s) & small molecule Kinase inhibitors (TKI’s)
  • Comparison of mAb’s and TKI’s
Targets and treatments part 2
  • Inhibitors of Receptor Tyrosine Kinases (eg. EGF-Receptor &HER2)
  • B-Raf and MEK inhibitors
  • PI3K, AKT & mTOR inhibitors
Targets and treatments part 3
  • Angiogenesis inhibitors (including thalidomide and derivatives)
  • ALK inhibitors
  • PARP inhibitors
Novel innovations to combat cancer
  • Targeting the hedgehog pathway
  • Immunotherapy
  • HSP90 inhibitors
Clinical trials and biomarkers
  • Considerations and new concepts in clinical trial design for targeted treatments
  • Case studies of the drug development process: gefitinib and crizotinib
  • The use of biomarkers to predict patient response